Adalimumab, an anti-TNF-α monoclonal antibody, was found to be effective for the treatment of luminal Crohn's disease (CD), but its efficacy for the prevention of postoperative recurrence of CD is still unknown. Here, we present a case series of six patients who underwent resection for an ileocecal stricture caused by CD. Surgery removed the involved ileocolon, and pathology confirmed the presence of a fibrotic stricture. Two weeks after the operation, they were given Adalimumab at the dose of 160/80/40mg every 2 weeks and were followed up. Since then, they have been disease-free for -3 years after surgery on clinical, radiological, and endoscopic/histological grounds (Crohn's Disease Activity Indexr110 in all occasions). Up to now, they have had no anemia, no increase in inflammatory indices, and no abnormal blood tests. These are the first cases, to our knowledge, in which Adalimumab has been successfully used to prevent the postsurgical recurrence of CD, an event so far considered to be mandatory. Further large placebo-controlled studies are necessary to show the therapeutic advantage and the economic implications of these observations.
|Number of pages||3|
|Journal||European Journal of Gastroenterology and Hepatology|
|Publication status||Published - Apr 2012|
- Antitumor necrosis factor α antibodies
- Crohn's disease
- Postsurgical relapse
ASJC Scopus subject areas